Publications by authors named "Aleksandra Tiemi Morikawa"
Safety and possible anti-inflammatory effect of paclitaxel associated with LDL-like nanoparticles (LDE) in patients with chronic coronary artery disease: a double-blind, placebo-controlled pilot study.
Front Cardiovasc Med
February 2024
Introduction: Studies in cholesterol-fed rabbits showed that anti-proliferative chemotherapeutic agents such as paclitaxel associated with solid lipid nanoparticles (LDE) have marked anti-atherosclerotic effects. In addition, association with LDE nearly abolishes paclitaxel toxicity. We investigated whether treatment with LDE-paclitaxel changes plaque progression by coronary CT angiography and is safe in patients with chronic coronary artery disease.
View Article and Find Full Text PDFArticle Synopsis
- Leishmaniasis is a global health issue that's often overlooked, with current treatments being inadequate.
- A study examined the use of triglyceride-rich nanoparticles (TGNP) as a delivery method for amphotericin B (AB) to treat Leishmania amazonensis, showing better tolerability and effectiveness compared to standard AB therapy.
- TGNP-AB demonstrated lower toxicity to healthy cells and significantly reduced the size of lesions and parasitic load in treated mice, highlighting its potential as a safer and more effective treatment option.
Lipid-based nanoparticle systems have been used as vehicles for chemotherapeutic agents in experimental cancer treatments. Those systems have generally been credited with attenuating the severe toxicity of chemotherapeutic agents. This study aimed to investigate the effects of associating paclitaxel (PTX) with a lipid-based nanoparticle system on a nonhuman primate, , documenting the toxicity as measured by serum biochemistry, which is a detailed analysis of blood and tissue.
View Article and Find Full Text PDF